FASEB Welcomes New President, Margaret K. Offermann, MD, PhD Created by on 07/11/2013
By Allison Lea
On the first of July, Margaret (Kenny) Offermann, MD, PhD, began her one-year term as FASEB President. She brings to the table an extensive background in medical oncology and biomedical research with senior leadership experience in academic, philanthropic, and private healthcare settings. In addition to her new role as FASEB President, Dr. Offermann is Managing Partner at the Salutramed Group, Inc., a consulting firm that provides analysis and support for critical decision-making and value creation for senior life science executives. She has been on the FASEB Board of Directors since 2008, and served as Vice President for Science Policy at FASEB in 2011 and 2012.
“American science and its biological research enterprise stand at a crossroad,” said Dr. Offermann. “After many years of contributions to health and well-being on a global scale, we now face an existential crisis with a material erosion of federal support. FASEB is taking a proactive role in working on issues that include the economic strength of the research enterprise, the quality of the scientific workforce, the ethical conduct of research, and relief from excessive regulatory burden. I am honored to serve as FASEB’s President during this challenging time, as we work to ensure the continuing vitality and growth of the American biological research enterprise.”
Dr. Offermann graduated magna cum laude from Mount Holyoke College with a BA in biochemistry and then went on to receive her MD and PhD in biochemistry from the Medical College of Virginia. She did postgraduate training at the University of Chicago Hospitals followed by the Dana Farber Cancer Institute and Harvard Medical School where she remained on the faculty for three years.
Dr. Offermann served on the faculty of Emory University School of Medicine from 1989 to 2007, where she rose to the rank of Professor of Hematology and Oncology and served as Co-Director of the MD-PhD training program, Associate Director of the Postgraduate Training Program in Hematology and Oncology, and Associate Director of the Winship Cancer Institute. Before starting the consulting firm in 2011, she spent three years as Deputy National Vice President for Research at the American Cancer Society, where she provided executive leadership for both intramural and extramural research programs.
The Federation welcomed three additional new FASEB officers as well: President-Elect Joseph R. Haywood, PhD; Vice President for Science Policy Peter A. Rubenstein, PhD; and Vice President-Elect for Science Policy Hudson H. Freeze, PhD. Dr. Haywood is Professor of Pharmacology and Toxicology and Assistant Vice President for Regulatory Affairs at Michigan State University. Dr. Rubenstein is a Professor in the Department of Biochemistry in the University of Iowa Carver College of Medicine, where he has been faculty member since 1977. Dr. Freeze is a Professor of Glycobiology and Director of the Genetic Disease Program at the Sanford-Burnham Medical Research Institute in San Diego.